|
|
 Previous Article | Table of Contents | Next Article 
Identification of a cell-surface antigen associated with activated T
lymphoblasts and activated platelets
DR Sutherland, E Yeo, A Ryan, GB Mills, D Bailey and MA Baker
Oncology Research Laboratories, Toronto General Hospital, Ontario, Canada.
We have identified and biochemically characterized an antigen, 8A3, which
is expressed on activated T lymphoblasts and activated platelets.
Monoclonal antibodies to 8A3 were raised against the primitive
lymphoid/myeloid cell line KG1a and additionally bound to the
erythroleukemia-derived cell line HEL, whilst exhibiting little or no
reactivity with a panel of other hematopoietic cell lines. The 8A3 antigen
was expressed on poorly differentiated T-cell leukemias and on
phytohemagglutinin-activated T-cells maintained in interleukin-2 (7,000
sites/cell). This antigen, though not detected on resting platelets, was
expressed on thrombin-activated platelets (2,000 sites/platelet).
Antibodies to 8A3 identified polypeptides of Mr 170,000 and 150,000 in
lysates of surface-iodinated KG1a cells, T lymphoblasts, and activated
platelets under both reducing and nonreducing conditions. However, peptide
mapping and susceptibily to glycosidases indicated that the 8A3 antigen was
a monomeric glycoprotein of Mr 170,000 which contained two N-linked
endoglycosidase H-sensitive glycans, and that the Mr 150,000 structure was
derived from it by proteolytic degradation. The 8A3 antigen was not
detectably phosphorylated in KG1a cells in vivo, nor did immune complexes
containing it exhibit kinase activity in vitro. Structural and serologic
characteristics of the 8A3 antigen indicate that it is different from other
previously described leukocyte activation antigens including transferrin
receptors, interleukin-2 receptors, members of the integrin family of
adhesion molecules, or "restricted" members of the leukocyte-common
antigen/CD45 cluster. Furthermore, the 8A3 antigen does not appear to be
related to the other previously described activation-specific platelet
molecule, GMP140/PADGEM. This antibody may be useful in monitoring T-cell
activation status in some clinical situations and in characterizing
clinically relevant activation-associated platelet membrane alterations.
Volume 77,
Issue 1,
pp. 84-93,
01/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. W. Finnson, B. Y. Y. Tam, K. Liu, A. Marcoux, P. Lepage, S. Roy, A. A. Bizet, and A. Philip
Identification of CD109 as part of the TGF-{beta} receptor system in human keratinocytes
FASEB J,
July 1, 2006;
20(9):
1525 - 1527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lin, D. R. Sutherland, W. Horsfall, N. Totty, E. Yeo, R. Nayar, X.-F. Wu, and A. C. Schuh
Cell surface antigen CD109 is a novel member of the alpha 2 macroglobulin/C3, C4, C5 family of thioester-containing proteins
Blood,
March 1, 2002;
99(5):
1683 - 1691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Schuh, N. A. Watkins, Q. Nguyen, N. J. Harmer, M. Lin, J. Y. A. Prosper, K. Campbell, D. R. Sutherland, P. Metcalfe, W. Horsfall, et al.
A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens
Blood,
March 1, 2002;
99(5):
1692 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
